Oral BBR-012 in the Treatment of Diabetic Foot Ulcers, Proof of Concept Study

Diabetic Foot Ulcer Clinical Trial

— BBR-012  

Official title:

A Randomised, Double-Blind, Repeat-Dose, Placebo-Controlled Phase IIa Proof of Concept Study to Investigate the Safety and Efficacy of Oral BBR-012 in Combination With Standard Medical Care in Diabetic Patients With Complicated Skin Ulceration on the Foot (Diabetic Foot Ulcer)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01342497
• Other study ID #: BBR-012CS01
• Status: Recruiting
• Phase: Phase 2
• First received: April 12, 2011
• Last updated: December 22, 2011
• Start date: July 2011
• Est. completion date: August 2012

Study information

• Verified date: December 2011
• Source: Bridge BioResearch Ltd.
• Contact: Andrew Boulton, Professor
• Phone: 0161 276 4406
• Email: aboulton[@]med.miami.edu
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The aim of this Clinical Proof of Principle study is to evaluate the effect of BBR-012 on the healing of complicated diabetic foot ulcers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: August 2012
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Main Inclusion Criteria:

• Aged =18

• Diabetes mellitus

• Ischaemic or neuro-ischaemic Diabetic Foot Ulcer below the malleolus, but not wholly on the sole of the foot (minimum size: 1 cm x 1 cm)

• Body Mass Index(BMI) =40 kg/m2

• Women of childbearing potential must use acceptable methods of birth control

• Written informed consent to participate in the study

• Patients must be able to speak English fluently and to understand English

Main Exclusion Criteria:

• Any uncontrolled illnesses (e.g. active malignancy, vasculitis) that, in the opinion of the investigator, would interfere with interpreting the results of the study

• Infected Diabetic Foot Ulcer based on the IDSA guidelines, i.e. presence of purulent secretions or at least two of the manifestations of inflammation (erythema, warmth, swelling or induration and pain or tenderness), and for whom, in the investigator's judgment, intravenous or oral antibiotic therapy is required

• Active osteomyelitis

• Wholly plantar Diabetic Foot Ulcer

• Suspected gangrenous tissue of the affected limb that cannot be removed with a single debridement

• Diabetic Foot Ulcer associated with prosthetic material or a device

• Received any potentially effective systemic antibiotic therapy for more than 24 hours during the 72-hour period before the screening visit

• Is receiving, or has received within the 14 days prior to the screening visit, any concomitant topical wound therapy (e.g., topical antimicrobial therapy, topical debriding agent, topical growth factor, topical skin replacement, or hyperbaric oxygen)

• Has received systemic corticosteroids, immunosuppressive agents, radiation therapy or chemotherapy within the 30 days prior to the screening visit.

• Hepatic impairment, renal impairment (defined as estimated glomerular filtration rate <10 mL/minute/1.73m2), hypersensitivity to isoniazid.

• High risk for tuberculosis, e.g. HIV positive, are immunosuppressed, or have active malignancy

• Symptoms of active or latent tuberculosis (based on specific history, physical examination, Interferon Gamma Release Assay (IGRA) test and chest X-Ray)

• Known or suspected drug or alcohol abuse or positive drugs of abuse test.

• Participating in any clinical study the 12 weeks before the screening visit

• Donation of more than 450 mL of blood in the 3 months before the screening visit, or 1200 mL blood in the 12 months before the screening visit.

• History of severe hypersensitivity or ongoing hypersensitivity that might affect the patient's suitability for the study (e.g. hypersensitivity to wound dressings), as judged by the investigator.

• History of allergy to, or insensitivity to, local anaesthetics

• Use of any prescribed or non-prescribed (over-the-counter) medication, including herbal medication (e.g., St. Johns Wort) that could possibly interfere with the objectives of this study (e.g., could affect the closure of chronic dermal ulceration), during 2 weeks (or 5 half-lives of the compound whichever is the longer) before the anticipated first dose of study medication. Occasional paracetamol for pain relief (maximum 2 g per 24 hours) and adrenergic nasal spray for relief of nasal congestion are allowed

• Having received BBR-012 or isoniazid within the 6 months prior to the screening visit

• Bleeding disorder or history of increased bleeding

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetic Foot
• Diabetic Foot Ulcer
• Foot Ulcer
• Ulcer

Intervention

Drug:
• isoniazide
Tablets, dosing 3 times daily, 12 weeks
• placebo
tablets, dosing 3 times daily, 12 weeks

Locations

Country	Name	City	State
United Kingdom	Tameside Hospital NHS Foundation Trust	Ashton-under-Lyne
United Kingdom	Bradford Royal Infirmary , Bradford Teaching Hospitals NHS Trust	Bradford
United Kingdom	Department of Wound Healing, School of Medicine, Cardiff University	Cardiff
United Kingdom	Chorley & South Ribble Hospital, Lancashire Teaching Hospitals Trust	Chorley
United Kingdom	Croydon University Hospital	Croydon
United Kingdom	Royal Infirmary of Edinburgh, Lothian University Hospital Trust	Edinburgh
United Kingdom	Gloucester Royal Hospital NHS Foundation Trust	Gloucester
United Kingdom	Manchester Royal Infirmary, University Department of Medicine	Manchester
United Kingdom	Nottingham City Hospital	Nottingham
United Kingdom	Derriford Hospital, Plymouth Hospitals NHS Trust	Plymouth
United Kingdom	Southampton Hospitals NHS Trust	Southampton

Sponsors (1)

Lead Sponsor	Collaborator
Bridge BioResearch Ltd.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of healing of diabetic foot ulcers (% reduction in area from baseline)		4, 8 and 12 weeks	No
Secondary	Rate of healing (change from baseline) as assessed by various scoring criteria: IDSA, modified ASEPSIS score, TEXAS Diabetic wound score, composite severity score and global clinical assessment		week 1, 2, 3, 4, 6, 8, 10, 12 and 13-14(follow up)	No
Secondary	Effect of BBR-012 on the level of ischemia (change from baseline as measured by tcpO2)		4, 8 and 12 weeks	No
Secondary	Effect of BBR-012 on microbiological outcome (presence of pathogens and outcome as compared to baseline)		week 1, 2, 3, 4, 6, 8, 10, 12 and 13-14(follow up)	No
Secondary	Safety and tolerability of BBR-012 as assessed by reported adverse events and safety laboratory parameters		from baseline visit to week 14	Yes